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SUMMARY Psoriasis is a chronic inflammatory disorder that usually 
requires long-term control. Etanercept has been shown to be 
effective in this disease. The efficacy and safety of etanercept were 
assessed in patients with psoriasis. In this 16-week open clinical 
trial, 29 patients with clinically stable psoriasis and psoriatic arthritis 
received etanercept (25 mg twice weekly) subcutaneously. All 
patients were evaluated for the psoriasis area, severity index (PASI) 
and Ritchie’s articular index (RAI) which measures arthritis disease 
activity. Improvement by 75 percent in PASI, considered significant 
for psoriasis remission, was observed in nearly sixty percent of 
patients after 12-week etanercept therapy. The percentage of PASI 
improvement was nearly 25% at two weeks, 52.3% at four weeks 
and 78% at 12 weeks of etanercept treatment, and was maintained 
for the next four weeks. Comparable results were obtained in the 
improvement of psoriatic arthritis symptoms, as improvement of 75 
percent in RAI was observed in 58.3 percent of patients after 12 
weeks of etanercept therapy. The percentage of RAI improvement 
was nearly 26% at two weeks, 40.5% at four weeks and 73.6% at 12 
weeks and 77.1% at 16 weeks of etanercept treatment. Etanercept 
was generally well tolerated, as most events were of mild severity. 
The treatment with etanercept led to significant improvement in 
patients with psoriasis over a period of 16 weeks.
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INTRODUCTION
 Psoriasis is a chronic inflammatory disorder 
that affects the skin and joints. The prevalence of 
the disease varies from 0.5% to 4.6%, with rates 
varying between countries and races. In Italy, it is 
approximately 2 percent of the population (1). The 
disease varies in severity; some patients have 
mild disease with isolated scaling erythematous 
plaques on the elbows, knees or scalp, whereas 
others can have up to 100% of their skin surface 
affected. Patients report substantial disease re-
lated impairment of health related quality of life, 
inability to work, and may face discrimination or 
depression (2,3). 
 Current therapies include topical and systemic 
treatments or phototherapy (4). Approximately 
25% of patients have moderate to severe disease 
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and require phototherapy or systemic treatment 
(5). Many therapies are associated with cumula-
tive toxicity that may limit their usefulness in this 
chronic disease (4,5). 
 For many years psoriasis was thought to be 
mainly epidermal disease, but the fact that im-
munosuppressive agents improve psoriasis has 
changed our knowledge about psoriasis. Although 
the pathogenesis of psoriasis is not fully under-
stood, there is evidence to support the role of the 
immune system, particularly T cells and cytokines 
(6,7). The concentration of the inflammatory cyto-
kine tumor necrosis factor (TNF) is higher in pso-
riatic lesions compared to the uninvolved skin and 
decreases after successive treatment of psoriasis, 
suggesting that TNF plays an important role in the 
pathogenesis of the disease (8,9). Based on these 
facts, a new class of agents, targeted biological 
therapies, have has been developed.
Etanercept is a soluble recombinant human TNF-
α-receptor fusion protein that prevents TNF-α-me-
diated cellular response competitively inhibiting its 
interaction with cell-surface receptors. Etanercept 
has been shown to be effective in patients with 
psoriasis (10,11). Based on these results we con-
ducted a study evaluating the efficacy and safety 
of etanercept in patients with psoriasis.
PATIENTS AND METHODS
 It was an open clinical trial that evaluated the 
efficacy of etanercept in the treatment of psoriasis 
and psoriatic arthritis over a period of 16 weeks.
Patients
 All patients enrolled in the study gave a writ-
ten informed consent before entering the study. 
Patients were eligible for the study if they were 
at least 18 years of age, with active but stable 
chronic plaque psoriasis. Patients were required 
to have a minimum psoriasis area and severity in-
dex (PASI) of 10 (indicating moderate to severe 
psoriasis) and an active psoriatic arthritis (defined 
as >3 tender or painful joints and >3 swollen joints, 
or Ritchie’s articular index /RAI/ >12) at the time 
of study enrolment. All patients had been previ-
ously treated with systemic treatments such as cy-
closporine, retinoids or methotrexate, resulting in 
inadequate response or intolerance of respective 
therapy. Disease-modifying antirheumatic agents 
were discontinued for at least 2 weeks before the 
study and were not allowed during the study. Oral 
retinoids, corticosteroids and phototherapy were 
discontinued for at least 4 weeks before the study 
and were not allowed during the study. Exclusion 
criteria were as follows: patients with autoimmune 
disorders or positive autoantibodies, infectious 
diseases on screening, positive history of tuber-
culosis, neoplastic disorders, heart failure or other 
serious diseases, pregnancy, and breast feeding. 
Patients with active guttate, erythrodermic or pus-
tular psoriasis were excluded from the study.
Study protocol
 Screening laboratory studies included hema-
tology, serum chemistry, urinalysis, blood culture 
and urinary culture tests, serum immunoglobulins, 
peripheral lymphocyte typing, Mantoux test, para-
neoplastic markers (CEA, GICA, CA19.9, TPA and 
PSA), autoantibodies (ANA, ENA, nDNA), rheu-
matoid factor, anti-streptolysin O, serum concen-
tration of C-reactive protein, and  erythrocyte sedi-
mentation rate. Instrumental tests included chest 
and hand x-rays.
 The measures of psoriasis activity included 
PASI with the assessment of surface area involve-
ment, infiltration, erythema and scaling of psoriatic 
plaques. The measures of arthritis disease activity 
included RAI. It is based on the summation of joint 
responses upon application of firm digital pres-
sure. The sum of RAI is 78 and reflects disease 
exacerbations and improvement induced by anti-
rheumatic agents.
 Control testing was performed at 2, 4, 8, 12 and 
16 weeks (T15, T30, T60, T90 and T120, respec-
tively). This testing consisted of physical examina-
tion, vital signs, measures of disease activity (pso-
riasis and psoriatic arthritis), laboratory studies 
(hematology parameters, serum chemistry with 
kidney and liver function tests), and monitoring for 
adverse events.
Treatment
 Patients received etanercept (Enbrel) at a dose 
of 25 mg twice weekly by subcutaneous route for 
16 weeks. During the study the patients were al-
lowed to use topical emollients only. No other sys-
temic or topical treatments for psoriasis were al-
lowed.
Statistical analysis
 All patients who completed at least a 2-week 
study period were included in the analysis. Statistical 
analysis was performed by use of specific StataSE/8 
software (Stata Corporation, TX, USA). Continuous 
efficacy variables (percentage change from base-
line) were ranked using a nonparametric Wilcoxon 
signed rank test with a significance level of 0.05.
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 A total of 29 Caucasians with active, clinically 
stable psoriasis and psoriatic arthritis, 19 (65.5%) 
male and ten female, aged 30 to 81 (mean age 
53.4) years, mean duration of psoriasis 23.7 years, 
were included in the study. All study patients had 
psoriatic arthritis, had previously received topical 
corticosteroids and/or topical vitamin D analogs 
and were non-responsive or intolerant to system-
ic treatments such as cyclosporine, retinoids or 
methotrexate. Of 29 study patients, 23 completed 
16-week (T120), 24 completed 12-week (T90), 28 
completed 4-week (T30) and all 29 patients com-
pleted 2-week (T15) study period.  
 All patients were evaluated for PASI and RAI 
measuring arthritis disease activity. An improve-
ment in PASI by 50%, 75% and 90% percent was 
recorded (Table 1). An improvement in PASI by 
75% (PASI 75) was considered significant for pso-
riasis remission. An improvement in RAI by 50%, 
75% and 90% was recorded (Table 2).
Safety
 Etanercept was generally well tolerated in our 
patient population. Most adverse events were of 
mild to moderate severity. No cases of tuberculo-
sis or severe infections were reported during the 
study. Two patients presented acute urticaria after 
two weeks of treatment and they withdrew from 
the study. One patient withdrew for psoriasis re-
activation and development of erythroderma. This 
patient, on the contrary, showed improvement in 
articular symptoms. Other side effects were of 
mild severity and they disappeared in the first two 
weeks of treatment. Two patients had injection-site 
reaction, two had nausea and headache, and two 
patients had transiently increased articular pain.
DISCUSSION
 Our study demonstrated the efficacy and toler-
ability of etanercept, a TNF-α antagonist, in the 
treatment of psoriasis, underscoring the role of 
TNF-α in the pathogenesis of this disease. In our 
study, etanercept induced marked clearance of 
psoriatic skin lesions and improvement of psoriatic 
arthritis symptoms. Significant improvement by at 
least 50% in PASI was achieved by three quarters 
of patients within the first 8 weeks of treatment with 
etanercept. An improvement by 75% in PASI 75, 
considered significant for psoriasis remission, was 
observed in nearly sixty percent of patients after 
12 weeks of therapy. The response to treatment 
with etanercept was rapid and effective. The mean 
percentage of PASI improvements from baseline 
as measured by this index was statistically sig-
nificant. The rate of PASI improvement was nearly 
25% after two weeks, 52.3% after four weeks and 
78% after 12 weeks of etanercept treatment, and 
was maintained for the next four weeks. Compa-
rable results were obtained in the improvement of 
psoriatic arthritis symptoms, as an improvement 
by 75% in RAI was observed in 58.3 percent of 
patients after 12 weeks of etanercept treatment. 
The rate of RAI improvement was nearly 26% af-
ter two weeks, 40.5% after four weeks, 73.6% af-
ter 12 weeks and 77.1% after 16 weeks of etaner-
cept therapy. We found psoriatic arthritis response 
to be slightly slower than but as effective as the 
clearance of psoriatic skin lesions. Other studies 
have also shown the efficacy of etanercept in pso-
riasis (10-12). Few controlled clinical trials have 
been conducted in patients with psoriatic arthritis 
and have shown inconsistent results (13-15). Cy-
closporine was compared with methotrexate in an 
open trial in psoriatic arthritis showing greater re-
sponses in arthritis measures with methotrexate, 
Table 1. Clinical improvement of psoriasis area and severity index (PASI) after 2, 4, 8, 12 and 16 
weeks of treatment with etanercept
Baseline T0 2 weeks T15 4 weeks T30 8 weeks 60 12 weeks T90 16 weeks T120
Median PASI 15.5 11.5 7.4 4.9 3.5 3.3
PASI 50 - 6/29 (20.6%) 15/28 (53.5%) 18/24 (75%) 22/24 (91.7%) 22/23 (95.6%)
PASI 75 - 2/29 (6.8%) 4/28 (14.2%) 12/24 (50%) 14/24 (58.3%) 14/23 (60.8%)
PASI 90 - 0/29 0/28 4/24 (16.6%) 8/24 (33.3%) 8/23 (34.7%)
% PASI 
improvement - 25.8 % 52.3% 68.4% 77.4% 78.7%
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whereas PASI improved more with cyclosporine 
(16). However, the cumulating toxicity of these 
agents was a limiting factor (15,17), posing the 
need of a therapy treating both psoriasis and pso-
riatic arthritis. 
 Health-related quality of life is impaired in pa-
tients with psoriasis; it strongly depends on its 
severity and may be improved with treatment 
(3,18,19). Increased levels of TNF-α are associ-
ated with major depression and it has been specu-
lated that inflammatory cytokines such as TNF-α 
may form a link between fatigue and depression 
(20-22). Etanercept treatment may relieve fatigue, 
sleepiness and depression associated with this 
debilitating disease (23). Rapid clearance of skin 
lesions is an important aspect of effective psoria-
sis management and may correlate with patient 
satisfaction with the treatment.
 Etanercept has been approved for the treat-
ment of rheumatoid arthritis since 1998. Long-term 
clinical safety studies in more than 2000 patients 
have shown continued efficacy and favorable risk-
benefit profile of etanercept (24). In our study in-
cluding 29 patients, etanercept was generally well 
tolerated, as most events were of mild severity. 
Adverse events included two cases of acute ur-
ticaria, one case of erythroderma, injection-site 
reactions, nausea, headache, and transiently in-
creased articular pain.
 Although long-time safety studies in psoriasis 
patients treated with etanercept are not available, 
data from patients with rheumatoid arthritis sug-
gest that the treatment with etanercept may be 
considered a viable option in the treatment of se-
lected patients with psoriasis. Future studies will 
reveal how this therapy will expand previously es-
tablished psoriasis treatment protocols.
Table 2. Clinical improvement of Ritchie’s articular index (RAI) after 2, 4, 8, 12 and 16 weeks of treatment 
with etanercept
Baseline T0 2 weeks T15 4 weeks T30 8 weeks T60 12 weeks T90 16 weeks 120
Median RAI 22.7 16.8 13.5 8.8 6.0 5.2
RAI 50 - 6/29 (20.6%) 12/28 (42.8%) 16/24 (66.6%) 21/24 (87.5%) 21/23 (89.4%)
RAI 75 - 3/29 (10.3%) 4/28 (14.2%) 9/24 (37.5%) 14/24 (58.3%) 14/23 (60.8%)
RAI 90 - 1/29 (3.4%) 3/28 (10.7%) 6/24(25%) 7/24 (29.1%) 10/23 (43.4%)
% RAI improvement - 25.9 % 40.5% 61.2% 73.6% 77.1%
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